公开(公告)号：US09572798B2

公开(公告)日：2017-02-21

申请号：US14429449

申请日：2013-09-27

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397 ,  A61K45/06

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

Abstract translation: 本发明涉及提供用于预防和/或治疗诸如动脉粥样硬化，高胆固醇血症，包括人在内的哺乳动物中的低HDL血液病的血脂异常状况的药物组合组合物和药物组合的问题。 一种用于预防和/或治疗血脂异常等的药物组合物，其包含（a）由通式（1）表示的化合物（式中各符号与说明书中所定义的相同）或其盐 或其溶剂合物和（b）胆固醇吸收抑制剂。

公开(公告)号：US20170112811A1

公开(公告)日：2017-04-27

申请号：US15399856

申请日：2017-01-06

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor. (1)

公开(公告)号：US20190167645A1

公开(公告)日：2019-06-06

申请号：US16272050

申请日：2019-02-11

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K45/06 ,  A61K31/397

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

公开(公告)号：US20140221390A1

公开(公告)日：2014-08-07

申请号：US14162181

申请日：2014-01-23

Applicant: Kowa Company, Ltd.

Inventor： Haruki Shibata ,  Yasunobu Yoshinaka ,  Kimiyuki Shibuya

IPC: C07D401/12

CPC classification number: C07D401/12 ,  A61K31/496

Abstract: Provided is a compound useful in the prevention and treatment of non-alcoholic steatohepatitis. A prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis which contains, as the active ingredient, 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide, an acid-addition salt thereof, or a solvate of the same.

Abstract translation: 提供了用于预防和治疗非酒精性脂肪性肝炎的化合物。 含有作为活性成分的2- [4- [2-（苯并咪唑-2-基硫基）乙基]哌嗪-1-基] -N- [2,4（ⅰ））的非酒精性脂肪性肝炎的预防和/或治疗剂 - 双（甲硫基）-6-甲基-3-吡啶基]乙酰胺，其酸加成盐或其溶剂合物。

公开(公告)号：US11013722B2

公开(公告)日：2021-05-25

申请号：US16272050

申请日：2019-02-11

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397 ,  A61K45/06

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

公开(公告)号：US20180185337A1

公开(公告)日：2018-07-05

申请号：US15904922

申请日：2018-02-26

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K45/06 ,  A61K31/397

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

公开(公告)号：US09931321B2

公开(公告)日：2018-04-03

申请号：US15399856

申请日：2017-01-06

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397 ,  A61K45/06

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor (1).

公开(公告)号：US20150196538A1

公开(公告)日：2015-07-16

申请号：US14429449

申请日：2013-09-27

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397

CPC classification number: A61K31/423 ,  A61K31/397 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

Abstract translation: 本发明涉及提供用于预防和/或治疗诸如动脉粥样硬化，高胆固醇血症，包括人在内的哺乳动物中的低HDL血液病的血脂异常状况的药物组合组合物和药物组合的问题。 一种用于预防和/或治疗血脂异常等的药物组合物，其包含（a）由通式（1）表示的化合物（式中各符号与说明书中所定义的相同）或其盐 或其溶剂合物和（b）胆固醇吸收抑制剂。

公开(公告)号：US10258609B2

公开(公告)日：2019-04-16

申请号：US15904922

申请日：2018-02-26

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397 ,  A61K45/06

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.